New drug shows promise for irreversible hair loss
NCT ID NCT05076006
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tested an experimental drug (a JAK/TYK2 inhibitor) in 51 adults with cicatricial alopecia, a type of scarring hair loss that destroys hair follicles permanently. The main goals were to check the drug's safety and to see how it affects certain genes in skin and blood samples. The drug is already being studied for other conditions and aims to reduce inflammation that causes scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.